Gerresheimer AG (GXI.DE) Stock Analysis & Winston Score

Gerresheimer makes the containers and delivery devices that hold and dispense medicines. Its core products include glass vials, syringes, insulin pens, inhalers, and drug packaging — sold to pharmaceutical and biotech companies around the world. The company is one of Europe's largest suppliers of specialty glass and plastic packaging for the healthcare industry. Gerresheimer earns revenue by selling these components directly to drug manufacturers, who use them to package and deliver their products to patients. The company operates globally, with major facilities across Europe, North America, and Asia, and generates roughly €1.8 billion in annual revenue. Its competitive position relies on strict regulatory certifications and long-term supply contracts, which make it costly for customers to switch suppliers. The key growth driver is rising demand for injectable drug delivery devices, particularly for GLP-1 drugs like Ozempic, though high debt levels and thin operating margins leave limited room for error if volumes disappoint.